Company news

Neuraxis, Inc. (AMEX:NRXS) news

Every Neuraxis, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Neuraxis, Inc. stock analysis →

Press releases & updates

NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth

August 11, 2026

NeurAxis Expands Payer Coverage with New Policies

August 4, 2026

NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth

May 12, 2026

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026

May 5, 2026

NeurAxis Expands Payer Coverage with Four New Medical Policies

April 22, 2026

NeurAxis, Inc. Announces Preferred Stock Dividend

April 10, 2026

NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results

March 19, 2026

NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026

March 12, 2026

NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway

January 8, 2026

NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives

December 19, 2025

NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain

December 1, 2025

NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives

November 12, 2025

NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues

November 11, 2025

NeurAxis : Quarterly Report for Quarter Ending September 30. 2025 (Form 10-Q)

November 10, 2025

NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025

November 4, 2025

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the A...

October 24, 2025

NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

September 18, 2025

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

August 12, 2025

NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

August 5, 2025

NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives

June 17, 2025

NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (...

June 10, 2025

NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 27, 2025

NeurAxis Announces Closing of $5.0 Million Registered Direct Offering

May 22, 2025

NeurAxis Announces $5.0 Million Registered Direct Offering

May 21, 2025

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

May 20, 2025

NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

May 12, 2025

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

May 5, 2025